EUCTR2011-001883-23-DK进行中（未招募）1 期
FAST- Febuxostat versus Allopurinol Streamlined Trial A prospective, randomised, open-label, blinded endpoint (PROBE) clinical trial evaluating long term cardiovascular safety of febuxostat in comparison with allopurinol in patients with chronic symptomatic hyperuricaemia - FAST- Febuxostat versus Allopurinol Streamlined Trial V 11.0
niversity of Dundee0 个研究点目标入组 5,706 人开始时间: 2011年8月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 5,706
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients aged 60 years or over with a least one additional risk factor.
- •*Risk Factors
- •Age =70 years (male) or =75 years (female)
- •Smoking (current or within the last 2 years)
- •Diabetes mellitus
- •Impaired glucose tolerance
- •Hypertension (SBP > 140mmHg and/or DBP > 90mmHg) or on antihypertensive therapy
- •Dyslipidaemia (investigator opinion)
- •CKD Stage 1-3
- •Microalbuminuria or proteinuria
- •Family history of coronary heart disease or stroke in first degree relative at age <55 years
- •Inflammatory arthritis (investigator opinion – including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis)
- •Chronic NSAID therapy (investigator opinion)
- •Peripheral vascular disease
- •Previous CV event (MI CVA or transient ischaemic attack)
- •Peripheral vascular disease (Investigator / clinical opinion)
- •Chronic obstructive pulmonary disease (COPD)
- •2. Patients who, in the opinion of the recruiting physician, require treatment for chronic hyperuricaemia where urate deposition has already occurred.
- •3. Patients who have received =90 days treatment with allopurinol, or =3 allopurinol prescriptions, within the previous 6 months.
- •4. Patients, who in the opinion of the study recruiting physician or site coordinator, are eligible for treatment with either allopurinol or febuxostat.
- •5. Patients who are willing to give permission for their paper and electronic medical records, hospitalisation data, prescribing data, and (in the event of their death) their death certification data to be accessed and abstracted by trial investigators.
- •6. Patients who are willing to be contacted and interviewed by trial investigators or delegates (suitably trained research nurses), should the need arise (e.g., for adverse event assessment and to determine whether an episode of acute gout has occurred).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3804
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1902
排除标准
- •1. Patients who have any contraindication to febuxostat or allopurinol (with reference to the summary of product characteristics).
- •2. Patients with severe renal impairment (eGFR <30 ml/min as defined by the Cockroft-Gault formula according to creatinine, age, sex and body weight.
- •3. Patients with moderate or severe hepatic impairment i.e. cirrhosis with clinical and/or biological decompensation (i.e. ascitis, lower limb oedema, icterus or increased prothrombin time >2X reference value)
- •4. Patients with a life-threatening co-morbidity or with a significant medical condition and/or conditions that would interfere with the treatment, safety or compliance with the protocol.
- •5. Patients with malignancy, including haematological malignancy.
- •6. Patients who have experienced either a myocardial infarction or stroke.
- •7. Patients whose behaviour or lifestyle would render them less likely to comply with study medication (i.e., abuse of alcohol, substance misuse, debilitating psychiatric conditions or inability to provide informed consent).
- •8. Patients with an acute gout flare or who are within 14 days of the resolution of a gout flare.
- •9. Patients currently participating in another clinical trial or who have participated in a trial in the previous 3 months.
研究者
相似试验
进行中（未招募）
1 期
Febuxoststat versus Allopurinol Steamlined Trial (FAST)Chronic symptomatic hyperuricaemicMedDRA version: 17.0Level: PTClassification code 10018627Term: GoutSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001883-23-GBniversity of Dundee5,706
进行中（未招募）
1 期
Febuxoststat versus Allopurinol Steamlined Trial (FAST)EUCTR2011-001883-23-SEniversity of Dundee5,706
进行中（未招募）
1 期
Febuxoststat versus Allopurinol Steamlined Trial (FAST)Chronic symptomatic hyperuricaemicMedDRA version: 19.0Level: PTClassification code 10018627Term: GoutSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001883-23-FIniversity of Dundee5,706
已完成
不适用
Febuxostat versus allopurinol streamlined trialGoutMusculoskeletal DiseasesISRCTN72443728niversity of Dundee (UK)6,128
已完成
3 期
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.GoutNCT00174915Takeda1,072